Top 1000 Global Biomanufacturing Facilities - Insights from real-time ranking of global biomanufacturing capabilities. - BioPharm International


Top 1000 Global Biomanufacturing Facilities
Insights from real-time ranking of global biomanufacturing capabilities.

BioPharm International
Volume 24, Issue 7, pp. 26-34

Biomanufacturing capacity drives regional clustering

Creating the Index
Numerous studies and articles have portrayed biopharmaceutical revenue (and profits) as the key factor in the development and success of regional clusters. Factors such as company profitability, access to funding sources, and access to high-value employee expertise are certainly related to company location. The primary factor for regional growth, however, appears to be presence of biomanufacturing facilities. Manufactured products, not R&D, make money, and profitable companies tend to attract or support co-location of other similar companies. The biopharmaceutical industry appears to prefer co-locating where others have had manufacturing success. Lower cost regions do not appear to effectively attract high value manufacturing operations. To this point, we note that much biomanufacturing capacity is located in California and other global regions where costs of business operations are relatively high.

There is obviously a good reason that the majority of successful companies (with marketed products) have and continue to invest in building their own facilities, while now often shifting their resources and activities out of R&D. Biopharmaceutical R&D involves developing knowledge and intellectual property which, ultimately, only have value when products are manufactured and sold. R&D centers and staff are cost, not profit, centers and are only as valuable as the commercialized products they produce. Manufacturing facilities are profit centers, and generally remain this way for decades. Related to this, manufacturing facilities are tangible assets that hold their value, even when resold. In contrast, biopharmaceutical R&D is increasingly something being contracted out, and sometimes abandoned. It is increasingly being replaced by licensing and collaborations with small R&D-intensive companies, with even the largest international companies now taking this approach to their long-term development. However, these and other companies, particularly including the more successful (profitable) ones, for good reason tend to build their own captive manufacturing facilities (or in some cases, contract out to just a few major CMOs with experience in commercial product manufacturing).

Global distribution

Table I: Concentration of biopharmaceutical manufacturing capacity (accessed June 20, 2011).
The site shows current, real-time distribution of biopharmaceutical manufacturing. Table I shows major regions of the world ranked by their relative BioManufacturing Facility Index Score.

Industry views on market priorities
The relative concentration of biomanufacturing facilities generally parallels the number of facilities operating in each region and the regional market for biopharmaceutical products. Thus, it is no surprise that the US and Europe are the primary driving forces in biomanufacturing. Together, the US and Europe account for 62.4% of the worldwide total (based on cumulative facilities index scores).

Industry views on the roles of China and India
For the foreseeable future, other regions, notably China and India, appear to have little chance of catching up with this lead, assuming that operations continue to be structured as they are currently. However, as the local industries grow in these and other developing regions, manufacturers and regions will surely gain more world-class-sized facilities and will increase their relative Index scores. The current lack of precedents for FDA and European Medicines Agency approval of biopharmaceuticals manufactured at facilities in India, China or other developing regions will create a hurdle for Western companies seeking to supply major world markets from manufacturing bases located in these countries. Any facilities based in developing countries that target lesser-regulated international markets will likely also be smaller scale, perhaps biogenerics manufacturers.

blog comments powered by Disqus



Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Janssen Partners with Transposagen Biopharmaceuticals for CAR-T Therapies
November 24, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here